NO20023829L - Proteosom influensavaksine - Google Patents

Proteosom influensavaksine

Info

Publication number: NO20023829L
Authority: NO; Norway
Prior art keywords: influenza vaccine; vaccines; proteosome; proteosome influenza; proteosomes
Prior art date: 2000-02-15

Application number

NO20023829A

Other languages

English (en)

Other versions

NO20023829D0 (no

Inventor

David S Burt

Gregory Lee White

Iii Louis F Fries

Kirkor Torossian

David Hugh Jones

Martin Plante

George H Lowell

Original Assignee

Id Biomedical Corp Quebec

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2002-08-13

Publication date

2002-08-13

2002-08-13 Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec

2002-08-13 Publication of NO20023829L publication Critical patent/NO20023829L/no

2002-08-13 Publication of NO20023829D0 publication Critical patent/NO20023829D0/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO20023829A 2000-02-15 2002-08-13 Proteosom influensavaksine NO20023829D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18247600P	2000-02-15	2000-02-15
PCT/US2001/005222 WO2001060402A2 (en)	2000-02-15	2001-02-15	Proteosome influenza vaccine

Publications (2)

Publication Number	Publication Date
NO20023829L true NO20023829L (no)	2002-08-13
NO20023829D0 NO20023829D0 (no)	2002-08-13

Family

ID=22668645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023829A NO20023829D0 (no)	2000-02-15	2002-08-13	Proteosom influensavaksine

Country Status (11)

Country	Link
US (3)	US6743900B2 (no)
EP (1)	EP1255561B1 (no)
JP (2)	JP3980884B2 (no)
AT (1)	ATE331530T1 (no)
AU (4)	AU2001238478C1 (no)
CA (1)	CA2400468C (no)
DE (1)	DE60121136T2 (no)
ES (1)	ES2267724T3 (no)
IL (2)	IL150602A0 (no)
NO (1)	NO20023829D0 (no)
WO (1)	WO2001060402A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2217325T5 (es) *	1995-09-18	2009-04-01	United States Army Medical Research Materiel Command (Usamrmc)	Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente.
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
JP3980884B2 (ja) *	2000-02-15	2007-09-26	アイディーバイオメディカルコーポレイションオブケベック	プロテオソーム・インフルエンザ・ワクチン
US7524509B2 (en) *	2001-03-09	2009-04-28	Id Biomedical Corporation Of Quebec	Proteosome-liposaccharide vaccine adjuvant
BR0214280A (pt)	2001-11-19	2005-01-11	Becton Dickinson Co	Composição farmacêuticas em forma particulada
BR0310042A (pt) *	2002-05-14	2005-04-05	Chiron Srl	Vacinas de combinação mucosal para meningite bacteriana
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
US7491395B2 (en)	2002-11-20	2009-02-17	Bestewil Holding B.V.	Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004045641A2 (en) *	2002-11-20	2004-06-03	Crucell Holland B.V.	Antigen-complexes
EP1447080A1 (en)	2003-02-13	2004-08-18	Bestewil Holding B.V.	Method for producing virosome-like particles
TWI329130B (en)	2003-06-19	2010-08-21	Bestewil Holding Bv	Functionally reconstituted viral membranes containing adjuvant
US7368537B2 (en)	2003-07-15	2008-05-06	Id Biomedical Corporation Of Quebec	Subunit vaccine against respiratory syncytial virus infection
WO2005027964A1 (en) *	2003-09-15	2005-03-31	Id Biomedical Corporation Of Quebec	Measles subunit vaccine
GB0323231D0 (en) *	2003-10-03	2003-11-05	Chiron Srl	Immunodiffusion assays
US8173140B2 (en) *	2003-10-22	2012-05-08	Id Biomedical Corporation Of Quebec	Compositions and methods for activating innate and allergic immunity
WO2006004749A2 (en) *	2004-06-25	2006-01-12	Id Biomedical Corporation Of Quebec	Compositions and methods for treating neurological disorders
RU2007103343A (ru) *	2004-06-30	2008-08-10	АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК (CA)	Вакцинная композиция и способы лечения коронавирусной инфекции
AU2006252342A1 (en) *	2005-06-02	2006-12-07	Alza Corporation	Method for terminal sterilization of transdermal delivery devices
US20080038294A1 (en) *	2006-03-22	2008-02-14	Kersten Alexander J	Intranasal or inhalational administration of virosomes
US8535683B2 (en) *	2006-03-22	2013-09-17	Abbott Biologicals B.V.	Intranasal or inhalational administration of virosomes
WO2008073490A1 (en) *	2006-12-12	2008-06-19	Carrington Laboratories Inc.,	Purification of influenza viral antigens
MX2009009912A (es)	2007-03-27	2010-01-18	Sea Lane Biotechnologies Llc	Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
NZ587798A (en) *	2008-03-18	2013-06-28	Novartis Ag	Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
CN102046656A (zh) *	2008-03-28	2011-05-04	航道生物技术有限责任公司	针对病毒抗原的中和性分子
KR100966566B1 (ko)	2009-01-29	2010-06-29	엘지전자 주식회사	효율적인 공용 ｅ-ｄｃｈ 관리를 위한 신호 전송 기법
CA2761681A1 (en)	2009-05-13	2010-11-18	Sea Lane Biotechnologies, Llc	Neutralizing molecules to influenza viruses
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
CN102482666B (zh)	2009-07-06	2017-02-08	变异生物技术公司	制备囊泡的方法和由其产生的制剂
US9907746B2 (en)	2009-07-06	2018-03-06	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
WO2011106525A2 (en)	2010-02-26	2011-09-01	The Brigham And Women's Hospital, Inc.	Methods of treating cerebral amyloid angiopathy
CN104203275A (zh)	2010-06-09	2014-12-10	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
US9610248B2 (en)	2010-07-06	2017-04-04	Variation Biotechnologies, Inc.	Compositions and methods for treating influenza
WO2012097347A1 (en)	2011-01-13	2012-07-19	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
EP2663327A4 (en)	2011-01-13	2015-12-02	Variation Biotechnologies Inc	COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US10300140B2 (en)	2011-07-28	2019-05-28	I2 Pharmaceuticals, Inc.	Sur-binding proteins against ERBB3
WO2013072768A2 (en)	2011-11-18	2013-05-23	Variation Biotechnologies, Inc.	Synthetic derivatives of mpl and uses thereof
US9975956B2 (en)	2011-12-22	2018-05-22	I2 Pharmaceuticals, Inc.	Surrogate binding proteins which bind DR4 and/or DR5
WO2013104995A2 (en)	2012-01-12	2013-07-18	Variation Biotechnologies, Inc.	Compositions and methods for treating viral infections
WO2013111012A2 (en)	2012-01-27	2013-08-01	Variation Biotechnologies, Inc.	Methods and compositions for therapeutic agents
KR101601393B1 (ko)	2014-02-20	2016-03-09	현대자동차주식회사	차량용 비상 버튼
SG11201903890QA (en)	2016-11-04	2019-05-30	Baxalta Inc	Adeno-associated virus purification methods
WO2019035972A1 (en) *	2017-08-16	2019-02-21	Georgia State University Research Foundation, Inc.	SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
CA3208643A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707543A (en)	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en)	1987-06-23	1998-03-10	Lowell; George H.	Immuno-potentiating systems for preparation of immunogenic materials
DE3830496C1 (de) *	1988-09-08	1996-09-19	Daimler Benz Aerospace Ag	Vorrichtung zum Erkennen und Verfolgen von Objekten
SK279209B6 (sk) *	1992-12-21	1998-08-05	Virologický Ústav Sav	Bivalentné imunogény a spôsob ich prípravy
US5576016A (en)	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en)	1993-10-29	1995-05-22	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
US5961970A (en)	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
ES2217325T5 (es) *	1995-09-18	2009-04-01	United States Army Medical Research Materiel Command (Usamrmc)	Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente.
ES1032221Y (es) *	1995-10-04	1996-11-01	Ferre Jose Manuel Rodriguez	Tobogan componible perfeccionado para uso infantil.
EP0929678A2 (en) *	1996-07-10	1999-07-21	ID Biomedical Corporation of Maryland	Protein and peptide vaccines for inducing mucosal immunity
JP3426177B2 (ja) *	1999-12-28	2003-07-14	明智セラミックス株式会社	鋳造用ストッパー
JP3980884B2 (ja) *	2000-02-15	2007-09-26	アイディーバイオメディカルコーポレイションオブケベック	プロテオソーム・インフルエンザ・ワクチン
US6726292B1 (en) *	2000-07-27	2004-04-27	Daimlerchrysler Corporation	Full off-set two-piece fiber reinforced composite wheel using spoke or web area box sections

2001
- 2001-02-15 JP JP2001559498A patent/JP3980884B2/ja not_active Expired - Lifetime
- 2001-02-15 WO PCT/US2001/005222 patent/WO2001060402A2/en active IP Right Grant
- 2001-02-15 AU AU2001238478A patent/AU2001238478C1/en not_active Expired
- 2001-02-15 US US09/788,280 patent/US6743900B2/en not_active Expired - Lifetime
- 2001-02-15 IL IL15060201A patent/IL150602A0/xx unknown
- 2001-02-15 AU AU3847801A patent/AU3847801A/xx active Pending
- 2001-02-15 CA CA2400468A patent/CA2400468C/en not_active Expired - Lifetime
- 2001-02-15 AT AT01910923T patent/ATE331530T1/de not_active IP Right Cessation
- 2001-02-15 DE DE60121136T patent/DE60121136T2/de not_active Expired - Lifetime
- 2001-02-15 ES ES01910923T patent/ES2267724T3/es not_active Expired - Lifetime
- 2001-02-15 EP EP01910923A patent/EP1255561B1/en not_active Expired - Lifetime
2002
- 2002-07-04 IL IL150602A patent/IL150602A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023829A patent/NO20023829D0/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/771,737 patent/US7399840B2/en not_active Expired - Lifetime
2006
- 2006-05-12 AU AU2006202003A patent/AU2006202003A1/en not_active Abandoned
- 2006-10-30 JP JP2006294115A patent/JP2007051157A/ja active Pending
2008
- 2008-06-24 US US12/144,722 patent/US20080260781A1/en not_active Abandoned
2009
- 2009-04-27 AU AU2009201657A patent/AU2009201657A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL150602A (en)	2010-12-30
EP1255561A2 (en)	2002-11-13
ES2267724T3 (es)	2007-03-16
AU2009201657A1 (en)	2009-05-21
AU2001238478C1 (en)	2006-11-09
AU2001238478B2 (en)	2006-06-01
AU2006202003A1 (en)	2006-06-01
CA2400468A1 (en)	2001-08-23
CA2400468C (en)	2012-12-18
US20040156867A1 (en)	2004-08-12
WO2001060402A3 (en)	2002-03-21
DE60121136T2 (de)	2007-06-06
DE60121136D1 (de)	2006-08-10
HK1052629A1 (en)	2003-09-26
AU3847801A (en)	2001-08-27
US20010053368A1 (en)	2001-12-20
ATE331530T1 (de)	2006-07-15
EP1255561B1 (en)	2006-06-28
US20080260781A1 (en)	2008-10-23
WO2001060402A2 (en)	2001-08-23
US7399840B2 (en)	2008-07-15
US6743900B2 (en)	2004-06-01
NO20023829D0 (no)	2002-08-13
JP2003522802A (ja)	2003-07-29
JP2007051157A (ja)	2007-03-01
JP3980884B2 (ja)	2007-09-26
IL150602A0 (en)	2003-02-12

Publication	Publication Date	Title
NO20023829L (no)	2002-08-13	Proteosom influensavaksine
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
ATE350057T1 (de)	2007-01-15	Impfstoffzusammesetzung
CY1110585T1 (el)	2015-04-29	ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
AR014182A1 (es)	2001-02-07	Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
MY126588A (en)	2006-10-31	Intranasal influenza virus vaccine
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
NO20015073D0 (no)	2001-10-18	Vaksiner
DE60144240D1 (de)	2011-04-28	Zusammensetzung mit immunogenen mikroteilchen
DK1259259T3 (da)	2011-08-01	Mucosal adjuvansformulering
UY26882A1 (es)	2002-03-22	Nuevo tratamiento
BR0010711A (pt)	2002-02-13	Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
ATE343375T1 (de)	2006-11-15	Impfstoff zur modulation zwischen t1 und t2 immunantworten
WO2002036160A3 (es)	2003-05-30	Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
DE69637435D1 (de)	2008-03-27	Saponin-zusammensetzungen und deren verwendung
AR020852A1 (es)	2002-05-29	Antigenos de vacuna de leptospira para la prevencion de leptospirosis
EP1721618A3 (en)	2007-01-10	Proteosome influenza vaccine composition
ATE353226T1 (de)	2007-02-15	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2002030458A8 (en)	2002-07-18	Yersinia adhesion protein as vaccine adjuvant
DK1490100T3 (da)	2012-03-12	Kombinerede DNA/proteinvaccinepræparater
AR037908A1 (es)	2004-12-22	Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus
WO2002072622A3 (en)	2003-04-17	Vaccine antigens against infection by chlamydia trachomatis
WO2005030802A3 (en)	2005-09-09	Antigens for an east coast fever vaccine

Legal Events

Date	Code	Title	Description
2011-07-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application